(Q28250382)

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

Cell signaling by receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

Incidence and epidemiology of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

Increased risk of brain metastases in patients with HER-2/neu-positive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

Clinical value of epidermal growth factor receptor expression in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

Tyrosine kinase inhibition: an approach to drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

A Phase I Study of Cetuximab/Paclitaxel in Patients with Advanced-Stage Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1183

10.1586/14737140.7.9.1183

21 January 2018

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

17892419

1 reference

Consolidated OpenCitations Corpus – April 2017